Differential Expression Spectrum of circRNA in Plasma Exosomes in Dilated Cardiomyopathy With Heart Failure

Shuai Xu; Ge Zhang; Xin Tan; Yiyao Zeng; Huimin Fan; Jiamin Gao; Zhen Qin; Fengyi Yu; Bin Ma; Ting Zhang; Hezi Jiang; Xian Li; Xiangyu Wang; Jili Fan; Xiaohong Bo; Yafeng Zhou; Junnan Tang

doi:10.1111/jcmm.70258

Article · 2024 Deep GEO

Differential Expression Spectrum of circRNA in Plasma Exosomes in Dilated Cardiomyopathy With Heart Failure

Journal of Cellular and Molecular Medicine

Full Authors

Shuai Xu
Ge Zhang
Xin Tan
Yiyao Zeng
Huimin Fan
Jiamin Gao
Zhen Qin
Fengyi Yu
Bin Ma
Ting Zhang
Hezi Jiang
Xian Li
Xiangyu Wang
Jili Fan
Xiaohong Bo
Yafeng Zhou
Junnan Tang

DOI / publisher Google Scholar search Cite

Official Abstract

Dilated cardiomyopathy (DCM), a form of non‐ischaemic myocardial disease, is characterised by structural and functional cardiac abnormalities. As defined by the World Health Organisation, DCM constitutes a significant cardiac pathology, leading to increased morbidity and mortality due to complications such as heart failure and arrhythmias. The diagnostic process for DCM predominantly employs echocardiography and MRI, with biomarkers like NT‐pro BNP and troponin providing supportive, yet non‐specific, evidence. Exosomes, small extracellular vesicles, play a critical role in intercellular communications by transferring biomolecules including lipids, proteins, messenger RNA (mRNA) and non‐coding RNA (ncRNA) to target cells, thereby influencing key cellular processes such as proliferation, differentiation, apoptosis, angiogenesis and immune modulation. Within the ncRNA category, circular RNAs (circRNAs) are notable for their cellular specificity and evolutionary conservation and are often implicated in the regulatory mechanisms underlying DCM and heart failure. This investigation employed next‐generation sequencing technology to analyse plasma exosomal circRNA profiles in DCM patients with chronic heart failure (CHF), compared to healthy controls. The analysis revealed distinct circRNA expression patterns, identifying 49 uniquely expressed circRNAs in the DCM cohort with CHF. These circRNAs were associated with several critical biological pathways, including the sequestration of extracellular ligands from receptors, N‐acetyltransferase activity, histone acetyltransferase activity and endocytic vesicle membrane composition. The findings of this study provide valuable insights into the pathophysiological mechanisms of DCM and offer evidence for improving clinical diagnostic methodologies.

Text reproduced verbatim from PMC (source); DOI; CC-BY-4.0.

Cite this paper

Plain citation

Shuai Xu, Ge Zhang, Xin Tan, Yiyao Zeng, Huimin Fan, Jiamin Gao, Zhen Qin, Fengyi Yu, Bin Ma, Ting Zhang, Hezi Jiang, Xian Li, Xiangyu Wang, Jili Fan, Xiaohong Bo, Yafeng Zhou, Junnan Tang. Differential Expression Spectrum of circRNA in Plasma Exosomes in Dilated Cardiomyopathy With Heart Failure. Journal of Cellular and Molecular Medicine. 2024;28(24):e70258. https://doi.org/10.1111/jcmm.70258

Author-controlled citation; verify against the publisher version of record.

BibTeX RIS / EndNote CSL JSON DOI

Research & review context

Research fields: Extracellular-vesicle biomarker research
Dilated cardiomyopathy and heart failure
Review topics: Circulating RNA biomarkers in cardiomyopathy
Plasma vesicle-associated circular RNA profiling
Scientific role: Small human DCM-HF plasma vesicle circRNA expression study with predicted regulatory relationships and external assay follow-up.
Evidence position: Human case-control profiling with small qRT-PCR evaluation; platform and naming discrepancies remain, and predicted networks are not demonstrated binding or clinical diagnostic utility.
Related concepts: Vesicle-associated circular RNA candidates
Expression profiling versus regulatory inference
Possible citation contexts: Background: complementary circulating RNA classes in cardiomyopathy biomarker research.
Evidence synthesis: DCM-HF vesicle-associated circRNA candidates, retaining the unresolved platform, count and naming limitations.

Possible literature-review contexts, not evidence of existing citations. Read the findings and Evidence Scope before citing the original article.

Questions & evidence · Evidence limits · Original article & citation downloads

Evidence Scale

Differential Expression Spectrum of circRNA in Plasma Exosomes in Dilated Cardiomyopathy With Heart Failure

Exploratory plasma exosomal circRNA profiling in DCM-HF reports 49 differential circRNAs and a small external qRT-PCR evaluation. The evidence page explicitly distinguishes the Methods microarray platform from sequencing terminology elsewhere in the article.

Discovery participants: 3 DCM patients and 5 healthy controls
External assay participants: 6 DCM patients and 4 healthy controls
Detected circRNAs: 865
Final differential circRNAs: 49: 27 upregulated and 22 downregulated
Results/Fig. 5 external panel: 9 circRNAs; Methods lists 10

Counting note

Discovery and external assay sample counts are reported separately; no participant-level deduplicated total is inferred. qRT-PCR technical replicates and circRNA/network counts are not additional participants. Nine is the Results/Fig. 5 panel count, while Methods lists ten. External validation denotes expression-assay follow-up, not prospective clinical validation.

Research Question

What plasma exosomal circRNA expression differences and predicted regulatory relationships were reported in DCM with heart failure, and how far does the small external assay evaluation support them?

Author Evidence Summary

The article compares DCM-HF and healthy plasma vesicle-associated RNA, with a discovery group of 3 patients and 5 controls and an external group of 6 patients and 4 controls. It reports 49 differential circRNAs, 27 upregulated and 22 downregulated, and computational enrichment and interaction analyses. A material platform-reporting difference is retained: Methods 2.7 describes the LC Human ceRNA Array V1.0 microarray, whereas the abstract and other passages call the work next-generation or ceRNA sequencing. This evidence page therefore uses expression profiling without treating the assay as definitively verified RNA sequencing. Results 3.7 and Fig. 5 describe nine externally assessed circRNAs; Methods 2.9 lists ten. Expression-profile differences in these small groups are exploratory evidence, not a prospectively validated DCM diagnostic test or proof of a causal circRNA mechanism.

Key Findings

KF1 The study describes a small discovery comparison and an external assay phase, but its platform terminology is internally inconsistent.

Methods specifies a microarray; sequencing labels elsewhere are not silently converted into a harmonized RNA-seq claim.

Evidence for KF1
Measure	Value
Discovery participants	3 DCM; 5 healthy controls
External participants	6 DCM; 4 healthy controls
Methods 2.7 platform	LC Human ceRNA Array V1.0 (Agilent array workflow)
Reporting difference	Abstract and other passages use sequencing terminology

Source locator: Methods 2.1 and 2.7; Fig. 1A; Results 3.7

Permalink to KF1

KF2 Plasma vesicle preparations were characterized by morphology, particle sizing and vesicle-marker readouts.

Characterization supports the studied vesicle preparation, not exclusive exosomal or cardiac tissue origin.

Evidence for KF2
Measure	Value
Median diameter reported	82 nm in DCM; 77 nm in controls
Fig. 1 marker findings	CD9 and CD63 detected; Calnexin not detected

Source locator: Results 3.1; Fig. 1B-E

Permalink to KF2

KF3 The final reported circRNA screen identified 49 differential features.

The circRNA-specific Results/Fig. 2 screen is reported without assuming that generic lncRNA/mRNA thresholds in Methods describe the same analysis.

Evidence for KF3
Measure	Value
Detected circRNAs	865
Final differential set	49
Upregulated / downregulated	27 / 22
Final reported screen	Absolute log2 fold change >0.5 and P<0.05

Source locator: Results 3.2; Table 1; Fig. 2B-C

Permalink to KF3

KF4 Predicted circRNA-target relationships were associated with functional and pathway annotations.

Computational enrichment is not a direct assay of circRNA-mediated function.

Evidence for KF4
Measure	Value
Candidate target genes used in the analysis	25
Reported functional examples	Extracellular ligand sequestration, acetyltransferase-related activity and endocytic vesicle membrane annotations

Source locator: Methods 2.8 and 2.10; Results 3.3-3.5; Fig. 3

Permalink to KF4

KF5 Interaction-network analyses nominated gene relationships, with unresolved differences in reported network and hub counts.

Results 3.6, Fig. 4 and Table 2 do not support one unambiguously reconciled hub-gene total.

Evidence for KF5
Measure	Value
Analysis	Predicted target/PPI networks
Count qualification	Results describes a 38-node network and 25 hubs; Fig. 4 calls 38 genes hubs
Table qualification	Table 2 is headed degree >5 but also lists degrees <=5

Source locator: Results 3.6; Fig. 4; Table 2

Permalink to KF5

KF6 Results and figure legends describe external qRT-PCR assessment of nine circRNAs and group-profile differences.

Methods lists ten candidates, whereas Results 3.7 and Fig. 5 describe nine; this is a reporting difference, not a silently corrected count.

Evidence for KF6
Measure	Value
External participants	6 DCM patients; 4 healthy controls
Panel described in Results/Fig. 5	9 circRNAs
Additional readouts	Euclidean expression distance and PCoA

Source locator: Methods 2.9; Results 3.7; Fig. 5

Permalink to KF6

Study Design & Analytical Framework

Study profile

Study Design: Small human case-control plasma vesicle RNA profiling with an external qRT-PCR comparison
Evidence Type: Exploratory human expression association, predicted regulatory networks and external assay evaluation
Population: DCM with chronic heart failure and healthy controls
Primary Endpoint: Between-group plasma exosomal circRNA expression differences
Secondary Endpoint: Predicted targets/pathways and external hub-circRNA expression-profile assessment
External dataset evaluation: Yes

Data modalities

plasma vesicle characterization
ceRNA microarray as described in Methods 2.7; sequencing terminology elsewhere is inconsistent
external qRT-PCR
target and PPI network prediction
enrichment and PCoA

What This Study Adds

A DCM-HF plasma vesicle-associated circRNA expression comparison complementary to miRNA profiling.
An article-reported 49-feature differential circRNA set and computational target/pathway hypotheses.
Small external qRT-PCR follow-up presented together with the relevant platform, count and naming limitations.

Evidence Scope

Supports

Exploratory circRNA expression differences in the analyzed DCM-HF and healthy samples.
A reported final set of 49 differential circRNAs.
Computational target, PPI and pathway prioritization.
An external qRT-PCR comparison of the panel described in Results and Fig. 5.

Does Not Establish

A definitively verified RNA-sequencing platform across all source descriptions.
A fully reconciled network hub count or a ten-circRNA validation result.
Direct biochemical circRNA-miRNA-target binding or a causal DCM mechanism.
Prospective diagnostic sensitivity, specificity, AUC or clinical utility.
Cardiac tissue origin of every circulating vesicle-associated circRNA.
Clinical treatment efficacy from the identified circRNA candidates.

Limitations

The discovery (3 versus 5) and external (6 versus 4) groups are small.
Methods 2.7 describes a ceRNA microarray, while the abstract and other passages describe sequencing; neither description is silently erased.
The Results/Fig. 5 nine-circRNA panel differs from the ten candidates listed in Methods 2.9.
Results 3.6, Fig. 4 and Table 2 contain differing node/hub descriptions; no corrected hub total is invented.
The source uses the name hsa-circ-76,771 in some passages and hsa-circ-0076771 in Table 1. These are not silently assigned an authoritative database identity.
Expression differences and predicted networks do not establish prospective diagnostic utility, tissue of origin or a causal mechanism.

When This Study Is Useful to Cite

CU1: Which study examined plasma exosomal circRNAs in DCM-HF?
A small discovery and external-assay study reported expression differences, with an explicit microarray-versus-sequencing reporting discrepancy.
Evidence: KF1
CU2: How were DCM circRNA vesicle preparations characterized?
The paper reports particle morphology, 82/77-nm median sizes and CD9/CD63/Calnexin readouts in Results/Fig. 1.
Evidence: KF2
CU3: Which differential circRNA landscape was associated with DCM-HF?
The final screen reports 49 circRNAs: 27 up and 22 down.
Evidence: KF3
CU4: What candidate functions were associated with DCM vesicle circRNAs?
Computational target and enrichment analyses nominate acetyltransferase and vesicle-related contexts, not established mechanisms.
Evidence: KF4
CU5: Can the circRNA interaction network be used as validated mechanistic evidence?
It is a predicted network; its hub-count descriptions are also inconsistent across Results, the figure and Table 2.
Evidence: KF5
CU6: What independent assay evidence exists for DCM exosomal circRNA candidates?
Results/Fig. 5 describe nine candidates tested in 6 DCM patients and 4 controls, while Methods lists ten.
Evidence: KF6

What This Study Should Not Be Cited to Claim

A definitively verified RNA-sequencing platform across all source descriptions.
A fully reconciled network hub count or a ten-circRNA validation result.
Direct biochemical circRNA-miRNA-target binding or a causal DCM mechanism.
Prospective diagnostic sensitivity, specificity, AUC or clinical utility.
Cardiac tissue origin of every circulating vesicle-associated circRNA.
Clinical treatment efficacy from the identified circRNA candidates.

Evidence Matrix

Row ID	Component	Context	Finding	Evidence Level	Scope	Source Locator	Evidence refs
evidence-dcm-circrna-platform	Study design and platform provenance	Discovery and external assay phases	The study describes a small discovery comparison and an external assay phase, but its platform terminology is internally inconsistent. Discovery participants: 3 DCM; 5 healthy controls; External participants: 6 DCM; 4 healthy controls; Methods 2.7 platform: LC Human ceRNA Array V1.0 (Agilent array workflow); Reporting difference: Abstract and other passages use sequencing terminology	Human observational profiling	Platform identity is not silently harmonized.	Methods 2.1 and 2.7; Fig. 1A; Results 3.7	KF1
evidence-dcm-circrna-vesicles	Vesicle characterization	Plasma vesicle preparation	Plasma vesicle preparations were characterized by morphology, particle sizing and vesicle-marker readouts. Median diameter reported: 82 nm in DCM; 77 nm in controls; Fig. 1 marker findings: CD9 and CD63 detected; Calnexin not detected	Specimen characterization	No claim of uniquely cardiac or exclusively endosomal origin.	Results 3.1; Fig. 1B-E	KF2
evidence-dcm-circrna-screen	Differential expression screen	865 detected circRNAs	The final reported circRNA screen identified 49 differential features. Detected circRNAs: 865; Final differential set: 49; Upregulated / downregulated: 27 / 22; Final reported screen: Absolute log2 fold change >0.5 and P<0.05	Exploratory human association	A differential-expression threshold is not a diagnostic cutoff.	Results 3.2; Table 1; Fig. 2B-C	KF3
evidence-dcm-circrna-pathways	Predicted targets and functions	25 candidate target genes in the reported analysis	Predicted circRNA-target relationships were associated with functional and pathway annotations. Candidate target genes used in the analysis: 25; Reported functional examples: Extracellular ligand sequestration, acetyltransferase-related activity and endocytic vesicle membrane annotations	Computational enrichment	No experimentally demonstrated circRNA mechanism.	Methods 2.8 and 2.10; Results 3.3-3.5; Fig. 3	KF4
evidence-dcm-circrna-network	Network interpretation and reporting limits	Results 3.6, Fig. 4 and Table 2	Interaction-network analyses nominated gene relationships, with unresolved differences in reported network and hub counts. Analysis: Predicted target/PPI networks; Count qualification: Results describes a 38-node network and 25 hubs; Fig. 4 calls 38 genes hubs; Table qualification: Table 2 is headed degree >5 but also lists degrees <=5	Computational network inference	Do not advertise a precisely reconciled or experimentally validated network.	Results 3.6; Fig. 4; Table 2	KF5
evidence-dcm-circrna-qpcr	External candidate expression assessment	6 DCM and 4 healthy samples	Results and figure legends describe external qRT-PCR assessment of nine circRNAs and group-profile differences. External participants: 6 DCM patients; 4 healthy controls; Panel described in Results/Fig. 5: 9 circRNAs; Additional readouts: Euclidean expression distance and PCoA	Small external assay evaluation	No prospective diagnostic utility or invented ROC performance.	Methods 2.9; Results 3.7; Fig. 5	KF6

Q&A

Was this DCM circRNA study performed by sequencing or microarray?

Methods 2.7 explicitly describes an LC Human ceRNA Array V1.0 microarray, but the abstract and other passages use sequencing terminology. The discrepancy is unresolved; the evidence summary calls it expression profiling.

Evidence: KF1

How large were the human discovery and assay groups?

The discovery comparison is 3 DCM patients versus 5 controls; the external comparison is 6 versus 4. The phases are not converted into an independently deduplicated total.

Evidence: KF1, KF6

How many differential circRNAs were reported?

The final Results/Fig. 2 set contains 49 circRNAs, 27 upregulated and 22 downregulated, among 865 detected circRNAs.

Evidence: KF3

What do the functional analyses establish?

They provide predicted target and pathway relationships. They do not demonstrate direct binding, target regulation or causal function in human DCM.

Evidence: KF4, KF5

Were nine or ten circRNAs evaluated externally?

Results 3.7 and Fig. 5 describe nine, while Methods 2.9 lists ten. The website preserves the Results count with the discrepancy stated explicitly.

Evidence: KF6

Does external expression-profile separation make this a validated diagnostic test?

No. The small external assay group and expression-distance/PCoA separation do not establish prospective diagnostic performance or clinical utility.

Evidence: KF6

Concepts & Entities

Disease

dilated cardiomyopathychronic heart failure

Specimen

plasma extracellular vesiclesexosomal circRNAs

Methods

ceRNA microarrayqRT-PCRtarget predictionprotein-protein interaction networkPCoA

Entities

circRNACD9CD63

Evidence

case-control expression profilingexternal assay evaluation

Related Research

Differential expression profiles of plasma exosomal microRNAs in dilated cardiomyopathy with chronic heart failure
Complementary plasma exosomal miRNA profiling in DCM-HF; the RNA classes and assay descriptions differ, and cohort independence across these papers has not been established. · DOI: 10.1111/jcmm.17789
Plasma Olink Proteomics Reveals Novel Biomarkers for Prediction and Diagnosis in Dilated Cardiomyopathy with Heart Failure
Related DCM-HF plasma biomarker research using targeted protein profiling, rather than vesicle circRNA profiling. The studies do not validate a combined diagnostic assay. · DOI: 10.1021/acs.jproteome.4c00522

Publication & Provenance

DOI: https://doi.org/10.1111/jcmm.70258
Doi Url: https://doi.org/10.1111/jcmm.70258
Publisher: https://onlinelibrary.wiley.com/doi/full/10.1111/jcmm.70258
PubMed: https://pubmed.ncbi.nlm.nih.gov/39719688/
Pmc Url: https://pmc.ncbi.nlm.nih.gov/articles/PMC11668728/
Review Basis: Published main text, tables and figure legends at the cited primary sources. No independent reanalysis of participant-level data; unresolved reporting differences are identified in the evidence scope.
Data Availability: The article provides data-availability statements but no stable study-specific accession was verified from the reviewed text. No GEO accession or code repository is invented.

Author-controlled evidence page for this publication. The evidence synthesis below is distinct from the published abstract and does not replace the version of record. Reported inconsistencies are qualified rather than silently corrected.

Study-level evidence table

Study-level author-maintained evidence summary. Not participant-level data and not a ready-to-pool meta-analysis dataset. For formal citation, use the original article DOI.

Download study-level evidence CSV (UTF-8)

Formula safety: cells starting with =, +, -, @ (after leading whitespace), or tab/CR/LF are prefixed with an apostrophe. Treat all cells as text; remove only that safety prefix when recovering the original string.

Verify publication identity

These records identify the same original work; database inclusion is not evidence of scientific validity or clinical benefit.

Publisher record PubMed 39719688 PMC PMC11668728 OpenAlex record

All Publications Homepage